HTB homepage • Conference reports • Articles by subject • Subscribe 30 March 2018 Contents Editorial 30 March 2018: vol 19 no 6 – CROI 2018 part 2 Conference reports CROI 2018: second reports Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV Statin use might reduce risk of cancer in HIV positive people Rate of bone loss on ART slows after the first year Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum Cure research at CROI 2018: defining and reducing the reservoir and the risks from interrupting treatment HIV prevention and transmission Update on PrEP IMPACT study (March 2018) Cure-related research Elite controllers: sex differences and factors associated with loss of immune control Assessing antiretroviral therapy interruptions in HIV cure research Other news US Congress rejects Trump’s proposed cuts to research budget for 2018 On the web HCV advocacy training manual PDFs 30 March 2018: vol 19 no 6 HTB homepage • Conference reports • Articles by subject • Subscribe
